Wall Street banks on OxyContin and spin-off generics

As if $3 billion in sales of Purdue Pharma’s OxyContin wasn’t enough, investors are now focusing on successful generic versions of the opioid painkiller for promising returns. According to this article from SeekingAlpha.com, Pfizer is the upcoming superstar, with its painkiller drugs Lyrica, Remoxy, Embeda, and Acurox totaling over $2 billion in annual sales and with an estimated growth potential of another $1 billion.

Realizing how much money is being made off of America’s obsession with prescription drugs makes these stories all the more tragic.

Read about Pfizer’s buyout of Oxy generics here.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Pharmaceutical Industry and tagged , , , , , , , , , . Bookmark the permalink.

2 Responses to Wall Street banks on OxyContin and spin-off generics

  1. Pingback: Purdue files suit to edge out generic Oxy competitor | Oxy Watchdog

  2. Pingback: Purdue continues to protect $3 billion patent on OxyContin | Oxy Watchdog

Leave a Reply

Your email address will not be published. Required fields are marked *